LUMIBIRD : QUANTEL MEDICAL ONE OF THE FIRST WINNERS OF THE FRANCE 2030 “MEDICAL IMAGING” CALL FOR PROJECTS
16 November 2023 - 3:45AM
LUMIBIRD : QUANTEL MEDICAL ONE OF THE FIRST WINNERS OF THE FRANCE
2030 “MEDICAL IMAGING” CALL FOR PROJECTS
Lannion, November 15, 2023 –
5:45pm
QUANTEL MEDICAL ONE OF THE FIRST WINNERS
OF THE FRANCE 2030 “MEDICAL IMAGING” CALL FOR PROJECTS
The LUMIBIRD Group (FR0000038242 -
LBIRD), the European leader for laser technologies, is announcing
that the HoloDoppler project led by its subsidiary Quantel Medical
has been selected as part of the Health section of France 2030,
financed by Bpifrance (French public investment bank) to receive
€2.8m of public funding, split between Quantel Medical and its
partners. HoloDoppler is moving forward in partnership with the
world’s most renowned research and hospital centers for
ophthalmology: the Quinze-Vingts National Ophthalmology Hospital,
the Adolphe de Rothschild foundation hospital and ESPCI
Paris.
The HoloDoppler project aims to create a
next-generation medical device for quantitative and non-invasive
angiography of the eye. It represents a response to an unmet
medical need, making it possible to measure ocular blood flow with
sufficient temporal and spatial resolution to effectively diagnose
and treat pathologies such as glaucoma or hypertension. The
quantitative biomarkers provided in terms of ocular blood flow
(speed, flow rate, resistivity) will lead to a companion diagnostic
for personalizing patient treatments and follow-up.
The €2.8m grant will cover 60% of the total
amount of the project (€4.7m), which aims to take this technology,
which is already operational, to a sufficient level of maturity for
it to be marketed globally. This involves creating databases taking
into account several hundred clinical examinations and
incorporating artificial intelligence to effectively capitalize on
these data.
The market for retina imaging devices is
currently estimated at €800m per year. The aim is to bring
HoloDoppler to the market within four years, targeting a market
share in time of around 5%.
Jean-Marc Gendre, Lumibird Medical CEO:
“HoloDoppler is in line with our strategy to further strengthen our
range of treatment lasers (glaucoma, diabetes) with a range of very
high-performance and strong value-added imaging equipment. The
French state’s support and the presence of world-renowned academic
and clinical partners will enable us to accelerate the product’s
development and place it with leading ophthalmology centers around
the world with a view to its international launch within the next
four years”.
LUMIBIRD is one of the world's leading
specialists in lasers. With 50 years of experience and a mastering
of solid state laser, laser diodes and fiber laser technologies,
the Group designs, manufactures and markets high performance lasers
for scientific (laboratories and universities), industrial
(manufacturing, defense, Lidar sensors) and medical (ophthalmology,
ultrasound diagnostic) markets. Born from the combination of
Keopsys Group with Quantel in October 2017, LUMIBIRD has more than
1 050 employees and over €191 million of consolidated
revenues in 2022 and is present in Europe, America and
Asia.LUMIBIRD shares are listed on the Euronext Paris B
Compartment. FR0000038242 – LBIRD
www.lumibird.comSince 2022, LUMIBIRD is part of
Euronext Tech Leaders
Contacts
LUMIBIRDMarc Le FlohicChairman and CEOTel. +33(0) 1 69 29 17
00info@lumibird.com |
LUMIBIRDSonia RutnamChief Financial and Transformation OfficerTel.
+33(0) 1 69 29 17 00info@lumibird.com |
CalyptusMathieu CalleuxInvestors RelationsTel. +33(0) 1 53 65 37
91lumibird@calyptus.net |
- 231115_Lumibird_HolodopplerEN
Quantel (LSE:0FRI)
Historical Stock Chart
From Apr 2024 to May 2024
Quantel (LSE:0FRI)
Historical Stock Chart
From May 2023 to May 2024